Amoy Diagnostics shareholder completes significant stake reduction

Ningbo Yixiang Own-Fund Investment Partnership, a shareholder in Amoy Diagnostics Co., Ltd., has concluded its previously announced share reduction plan. The plan, initially disclosed on May 6, 2025, aimed to reduce Yixiang Investment's holding of 20,026,900 shares, representing 5.10% of the company's total share capital.

Yixiang Investment successfully reduced its holdings by a total of 11,295,900 shares, which accounts for 2.89% of Amoy Diagnostics' total share capital. This was executed through a combination of centralized bidding and block trading. Centralized bidding sales, occurring between July 23, 2025, and August 27, 2025, involved 3,465,200 shares at an average price of RMB 24.35 per share. Block trading, conducted between August 1, 2025, and August 21, 2025, saw the sale of 7,830,700 shares at an average price of RMB 21.69 per share.

Following this reduction, Yixiang Investment's total holding in Amoy Diagnostics now stands at 8,731,000 shares, representing 2.23% of the total share capital. This transaction means Yixiang Investment is no longer a shareholder holding 5% or more of the company's shares. The company confirmed that this share reduction complies with relevant regulations and does not impact the company's governance structure or control.